Summary
Core view: Sai Life Sciences grew Q1 FY27 revenue 12% and PAT 21-22% year-on-year, with CRO growing faster (26%) than CDMO (6%). Growth was healthy and margin expanded, but it did not clearly exceed the market's high expectations, and the stock fell modestly post-results despite double-digit growth, reflecting a valuation that already prices in continued execution against the company's 15-20% long-term growth guidance.
Sai Life Sciences is a contract research, development and manufacturing organisation (CRDMO) serving global innovator pharma customers, with CDMO (60% of Q1 FY27 revenue) and CRO (40%) segments.
Q1 FY27 Snapshot
Revenue₹554 Cr+12% YoY
PAT₹73 Cr+21-22% YoY
EBITDA margin27.0%Up ~2 pts YoY
EPS (Q1)₹3.46+19.3% YoY
| Segment | Q1 FY27 mix | YoY growth |
|---|---|---|
| CDMO | 60% | +6% |
| CRO | 40% | +26% |
Business Quality And Mix
Strengths
- Diversified CRDMO model spanning discovery-to-commercial manufacturing.
- CRO segment growing faster (26% YoY) than CDMO.
- PAT margin improved to 13% from 12% YoY.
- Reiterated 15-20% long-term revenue growth guidance.
Constraints
- CDMO growth (6% YoY) is slower than the CRO segment.
- Elevated valuation leaves little room for a quarter that merely meets expectations.
- Large planned capex (₹1,100-1,300 crore for FY27) adds execution risk.
- Global pharma R&D spending cycles can affect CRO demand.
Growth Drivers And Capacity Economics
Long-term growth guidance15-20% annuallyReiterated
EBITDA margin guidance28-30%Reiterated
FY27 capex₹1,100-1,300 CrCapacity and peptide capability
Growth drivers include new molecule and peptide capability additions, continued CRO demand from global innovator pharma, and capacity expansion funded by a large FY27 capex programme.
Management Guardrails And Credibility
| Objective | Target | Assessment |
|---|---|---|
| Revenue growth | 15-20% annually | Reiterated in Q1 FY27; the 12% YoY actual growth is within range but toward the lower end. |
| EBITDA margin | 28-30% | Q1 FY27's 27% is just below the guided range; achieving the top end requires continued mix improvement. |
| Capex | ₹1,100-1,300 Cr for FY27 | Substantial investment supporting capacity and peptide capability, with associated execution risk. |
Financial Quality
PAT margin13%Up from 12% YoY
EBITDA margin27%Up from ~25% YoY
Capex plan₹1,100-1,300 CrFY27
CRO growth+26% YoYFaster than CDMO
| Quality test | Reading | Interpretation |
|---|---|---|
| Earnings quality | PAT +21-22% YoY on broad-based growth | Genuine operating improvement across both CRO and CDMO, not concentrated in one segment. |
| Margin trend | EBITDA margin ~27% vs guided 28-30% | Slightly below the guided range; needs to close the gap as mix and utilisation improve. |
| Growth guidance vs actual | 12% YoY vs 15-20% guided range | Actual growth is at or below the low end of guidance this quarter. |
Valuation
Key Risks
- Capex execution delays on the ₹1,100-1,300 crore FY27 programme.
- Global pharma R&D spending cycles affecting CRO demand.
- CDMO project concentration and timing.
- Elevated valuation leaves little room for a miss.
- Currency and input-cost volatility.
Projection: Next 2-4 Quarters
Investor Watchlist
- CRO vs CDMO growth mix each quarter.
- EBITDA margin trend versus the 28-30% guided range.
- Capex progress and capacity commissioning.
- Peptide and new-technology capability additions.
- Order book and customer concentration disclosures, if provided.